生物活性

• 描述SB-9200 has a broad-spectrum antiviral activity against RNA viruses including hepatitis C virus (HCV), norovirus, respiratory syncytial virus and influenza and has demonstrated activity against hepatitis B virus (HBV) in vitro and in vivo.
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT03434353	Chronic Hepatitis b	Phase 2	Recruiting	June 2020	Hong Kong ... more >> Alice Ho Miu Ling Nethersole Hospital Recruiting Hong Kong, Hong Kong Prince of Wales Hospital-HK Recruiting Hong Kong, Hong Kong Korea, Republic of Korea University Ansan Hospital Recruiting Ansan, Korea, Republic of, 425-707 Keimyung University Dongsan Medical Center Recruiting Daegu, Korea, Republic of, 41931 Kyungpook National University Hospital Recruiting Daegu, Korea, Republic of, 41944 Inje University Ilsan Paik Hospital Recruiting Ilsan, Korea, Republic of, 10380 Severance Hospital, Yonsei University Health System Recruiting Seoul, Korea, Republic of, 03722 Asan Medical Center Recruiting Seoul, Korea, Republic of, 05505 Gangnam Severance Hospital, Yonsei University Health System Recruiting Seoul, Korea, Republic of, 06273 Catholic University of Korea, Seoul Saint Mary's Hospital Recruiting Seoul, Korea, Republic of, 06591 SMG-SNU Boramae Medical Center Recruiting Seoul, Korea, Republic of, 07061 Korea University Guro Hospital Recruiting Seoul, Korea, Republic of, 08308 Collapse <<
  NCT03493698	Drug Interaction Potentiation	Phase 1	Completed	-	Netherlands ... more >> University Medical Center Groningen Groningen, Netherlands Collapse <<
  NCT01803308	Hepatitis C Infection	Phase 1	Completed	-	Australia, Victoria ... more >> Nucleus Network, Austin Hospital Heidelberg, Victoria, Australia, 3084 Nucleus Network, The Alfred Hospital Melbourne, Victoria, Australia, 3004 Australia, Western Australia Linear Clinical Research, The Queen Elizabeth II Medical Centre Nedlands, Western Australia, Australia, 6009 New Zealand Primorus Clinical Trials Ltd Christchurch, New Zealand, 8011 Collapse <<

• 更多
• 参考文献

• [1] Jones M, Cunningham ME, et al. SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants. J Med Virol. 2017 Mar 17.

  [2] Suresh M, Korolowicz KE, et al. Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks. PLoS One. 2017 Jan 5;12(1):e0169631.